Drug intelligence / Profile preview

Carboplatin + Cisplatin + Pemetrexed + rh-endostatin

Development stage: Unknown
Lead developer: Johnson Matthey
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Intravenous, Intrapleural

Overview

This is a combination therapy consisting of three chemotherapy agents (carboplatin, cisplatin, and pemetrexed) plus a targeted anti-angiogenic agent (rh-endostatin/Endostar). The combination has been studied primarily for advanced non-small cell lung cancer. Pemetrexed is an antifolate agent that disrupts folate-dependent metabolic processes essential for cell replication. Carboplatin and cisplatin are platinum-based chemotherapy drugs that work by damaging DNA and preventing cancer cells from dividing. Rh-endostatin (recombinant human endostatin, also known as Endostar) is an anti-angiogenic agent that targets new capillary endothelial cells around tumors, inhibiting tumor blood vessel formation.

Targets

GART (GAR transformylase)Integrin (Integrin family)TS (Thymidylate synthase)ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)DHFR (Dihydrofolate reductase)VEGFR (VEGFR family)DNA

Beyond the preview

Go deeper on Carboplatin + Cisplatin + Pemetrexed + rh-endostatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carboplatin + Cisplatin + Pemetrexed + rh-endostatin.

Explore the full profile